Compugen (NASDAQ:CGEN) and BIO-TECHNE (NASDAQ:TECH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Insider & Institutional Ownership
21.7% of Compugen shares are held by institutional investors. Comparatively, 93.9% of BIO-TECHNE shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 3.8% of BIO-TECHNE shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Compugen has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, BIO-TECHNE has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Earnings and Valuation
This table compares Compugen and BIO-TECHNE’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BIO-TECHNE||$642.99 million||9.18||$126.15 million||$4.07||38.38|
BIO-TECHNE has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than BIO-TECHNE, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings for Compugen and BIO-TECHNE, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Compugen presently has a consensus price target of $9.00, suggesting a potential upside of 172.73%. BIO-TECHNE has a consensus price target of $185.71, suggesting a potential upside of 18.88%. Given Compugen’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Compugen is more favorable than BIO-TECHNE.
BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.8%. Compugen does not pay a dividend. BIO-TECHNE pays out 31.4% of its earnings in the form of a dividend.
This table compares Compugen and BIO-TECHNE’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
BIO-TECHNE beats Compugen on 10 of the 16 factors compared between the two stocks.
Compugen Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company’s pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.
BIO-TECHNE Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Compugen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Compugen and related companies with MarketBeat.com’s FREE daily email newsletter.